Zobrazeno 1 - 10
of 203
pro vyhledávání: '"Shuji, Murakami"'
Autor:
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Publikováno v:
Thoracic Cancer, Vol 15, Iss 17, Pp 1343-1349 (2024)
Abstract Background Atezolizumab, one of the immune checkpoint inhibitors, has been approved as an adjuvant treatment following resection and platinum‐based chemotherapy in patients with stage II–IIIA non‐small cell lung cancer with 1% or more
Externí odkaz:
https://doaj.org/article/71efbf3a4aae40ef8a8cbd9e59852ae7
Autor:
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Publikováno v:
Thoracic Cancer, Vol 15, Iss 6, Pp 458-465 (2024)
Abstract Background The terminology for lung cancer diagnosis in small biopsies was adopted in the 2015 World Health Organization classification. If non‐small cell lung cancer (NSCLC) has no clear adenocarcinoma (AD) or squamous cell carcinoma morp
Externí odkaz:
https://doaj.org/article/45286cfd14ba4c0ca4e1c11eca756d80
Autor:
Shuji Murakami, Kanako Shinada, Yuka Otsutsumi, Fumiko Komine, Yuan Yuan, Junko Nakamura, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose, Haruhiro Saito
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Purpose Genetic mutation detection has become an important step in nonsmall‐cell lung cancer (NSCLC) treatment because of the increasing number of drugs that target genomic rearrangements. A multiplex test that can detect multiple gene mut
Externí odkaz:
https://doaj.org/article/1402e9a4128a4aaf8f054c648279390c
Autor:
Johan F. Vansteenkiste, MD, PhD, Jarushka Naidoo, MB, BCH, MHS, Corinne Faivre-Finn, MD, PhD, Mustafa Özgüroğlu, MD, Augusto Villegas, MD, Davey Daniel, MD, Shuji Murakami, MD, Rina Hui, M.B.B.S., PhD, Ki Hyeong Lee, MD, Byoung Chul Cho, MD, PhD, Kaoru Kubota, MD, PhD, Helen Broadhurst, MSc, Catherine Wadsworth, BVSc, Michael Newton, PharmD, Piruntha Thiyagarajah, MD, Scott J. Antonia, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100638- (2024)
Introduction: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression a
Externí odkaz:
https://doaj.org/article/86197b668ce247a6aed1dbb164a76e9d
Publikováno v:
Thoracic Cancer, Vol 14, Iss 28, Pp 2886-2889 (2023)
Abstract Among epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancers, squamous cell carcinoma is less common and shows lower responsiveness to first‐generation EGFR tyrosine kinase inhibitors (TKIs) compared to a
Externí odkaz:
https://doaj.org/article/be5a3d6e65064922b52c211e7b9f16e7
Autor:
Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Terufumi Kato, Tetsuro Kondo, Huihui Xiang, Rika Kasajima, Hidetomo Himuro, Kayoko Tsuji, Yasunobu Mano, Mitsuru Komahashi, Yohei Miyagi, Haruhiro Saito, Koichi Azuma, Shuichiro Uehara, Tetsuro Sasada
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1831 (2024)
Neutrophil extracellular traps (NETs) released from neutrophils are related to cancer progression. However, the relationship between the therapeutic effects of immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-PD-L1 antibodies and plasma
Externí odkaz:
https://doaj.org/article/4b39897048e4485b88664befbd1be51d
Autor:
Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, Kenji Chibana, Kyoichi Kaira, Kyoichi Okishio, Eiki Ichihara, Shuji Murakami, Mototsugu Shimokawa, Nobuyuki Yamamoto
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: ALK-tyrosine kinase inhibitors (ALK-TKIs) are effective for treating non-small-cell lung cancer with ALK gene rearrangement; however, resistance is inevitable. Brigatinib is a unique ALK-TKI that is effective against many resistance mutat
Externí odkaz:
https://doaj.org/article/49d4fe358af74383a12fd7f0ddcc1676
Autor:
Daichi Fujimoto, Satoru Miura, Keisuke Tomii, Hiromitsu Sumikawa, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Toshihide Yokoyama, Takashi Kijima, Tetsuhiko Asao, Motohiro Tamiya, Atsushi Nakamura, Hiroshige Yoshioka, Takaaki Tokito, Shuji Murakami, Akihiro Tamiya, Hiroshi Yokouchi, Satoshi Watanabe, Ou Yamaguchi, Ryotaro Morinaga, Takayuki Jodai, Kentaro Ito, Yoshimasa Shiraishi, Yoshihito Kogure, Ryota Shibaki, Nobuyuki Yamamoto
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated
Externí odkaz:
https://doaj.org/article/d7954e13f28249d198db8ce843bb07a9
Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
Autor:
Shuji Murakami, Tomoyuki Yokose, Kanako Shinada, Testuya Isaka, Kengo Katakura, Ryouta Ushio, Tetsuro Kondo, Terufumi Kato, Hiroyuki Ito, Haruhiro Saito
Publikováno v:
Thoracic Cancer, Vol 13, Iss 22, Pp 3217-3224 (2022)
Abstract Background As the number of genetic mutations that must be tested increases, the Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer‐related genes is becoming the main test used in preference to single‐molecu
Externí odkaz:
https://doaj.org/article/9e33169d510549aeb20e5bc54e6125f5
Autor:
Tetsuro Sasada, Koichi Azuma, Haruhiro Saito, Norikazu Matsuo, Takaaki Tokito, Yohei Miyagi, Terufumi Kato, Tomoyuki Tagami, Kenta Murotani, Feifei Wei, Yoshiro Nakahara, Taku Kouro, Yuka Igarashi, Tetsuro Kondo, Shuji Murakami, Ryo Usui, Hidetomo Himuro, Shun Horaguchi, Kayoko Tsuji, Tatsuma Ban, Tomohiko Tamura
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Immune checkpoint inhibitor (ICI) therapy has substantially improved the overall survival (OS) in patients with non-small-cell lung cancer (NSCLC); however, its response rate is still modest. In this study, we developed a machine learning-
Externí odkaz:
https://doaj.org/article/2dcd6e25692a40a68ca6114c57cd1999